"This has had an enormous impact," Johnson & Johnson's (JNJ -0.2%) head of global regulatory...

"This has had an enormous impact," Johnson & Johnson's (JNJ -0.2%) head of global regulatory affairs says during a congressional briefing on the FDA's power to grant Breakthrough Therapy designation. Bloomberg highlights JNJ and Pharmacyclics' (PCYC +1%) recent NDA for ibrutinib and notes that, thanks to the new designation, the companies will likely get a response from the regulator two years ahead of schedule.